Retrospective analysis of serum free light chain reference intervals and risk for monoclonal gammopathy suggests different limits than those in international guidelines
- 30 June 2023
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 118, 110604
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Screening Panels for Detection of Monoclonal GammopathiesClinical Chemistry, 2009
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2008
- Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseasesClinica Chimica Acta, 2007
- Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple MyelomaClinical Cancer Research, 2005
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M ProteinsAmerican Journal of Clinical Pathology, 2005
- Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 2004
- Serum free light chains for monitoring multiple myelomaBritish Journal of Haematology, 2004
- Quantitative Analysis of Serum Free Light ChainsAmerican Journal of Clinical Pathology, 2003